Theraclone Sciences theraclone-sciences.com


Public list: Pharma Startups (4743) Cancer Therapeutics (1148)

Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the IĀSTAR discovery platform and scaled for industrial production. Such human ...Show all

Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system ...Show all

Company (Alive / Active)

Phone: 206-805-1600

Fax: 206-805-1699

1124 Columbia Street
Suite 300
Seattle, 98104
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Theraclone Sciences $63.8M May 7, 2015
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Theraclone Sciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 15 investors

Competitors

Company Status Description Investors

Amplimmune Immunology

Gaithersburg, Maryland, United States
AcquiredAmplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with ...Show allLogin to see details

MacroGenics

Rockville, Maryland, United States
IPO / Went publicMacroGenics is a biotechnology company focused on the discovery, development and delivery to patients of biologics for treatment of cancer, autoimmune disorders and infectious diseases. MacroGenics has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' research is based on three core technology platforms, which include: (1) a leading research capability for screening and tar...Show allLogin to see details
See all 15 competitors